Provided By GlobeNewswire
Last update: May 27, 2025
WAYNE, Pa. and ROCKVILLE, Md., May 27, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that management will participate in the following investor conferences in June.
Read more at globenewswire.comNASDAQ:AVTX (7/11/2025, 8:00:02 PM)
4.78
-0.12 (-2.45%)
Find more stocks in the Stock Screener